NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study

NeuroSense (NRSN) Therapeutics announced new positive findings based on plasma samples from its Phase-2b PARADIGM study. These results indicate that PrimeC produced robust, statistically significant reductions in multiple microRNAs that are consistently implicated in Alzheimer’s disease pathology – changes that reflect reduction of neuroinflammatory and neurodegenerative activity. Key Highlights: PrimeC treatment significantly reduced several AD-associated microRNAs, including miR-146a-5p, miR-21-5p, miR-let-7a-5p and miR-let-7e-5p, measured as change from baseline, while no significant change was observed in the placebo group over time. MicroRNAs are master regulators of gene expression. The miRNAs described above are associated with neuroinflammation, amyloid and tau pathology, synaptic dysfunction which relate to a cognitive decline. By lowering these biomarkers, PrimeC demonstrated the ability to directly target biological pathways central to AD progression, supporting its potential as a disease-modifying therapy.